Sfoglia per Autore
Quale strategia per la gestione dell’anemia in corso di triplice terapia anti-HCV?
2013 E.Salomoni; F.Baragli; C.Innocenti; G.Corti
CMV AND EBV REACTIVATION AFTER AUTOLOGOUS HAEMOPOIETIC STEM CELL TRANSPLANTATION WITH BEAM CONDITIONING REGIMEN FOR MULTIPLE SCLEROSIS AND LYMPHOMA: A RETROSPECTIVE SINGLE CENTER CASE-CONTROL STUDY
2014 Di Gioia, M; Innocenti, C; Donnini, I; Nozzoli, C; Bosi, A; Guidi, S; Rigacci, L; Repice, A; Massacesi, L; Portaccio, E; Amato, MP; Saccardi, R
Safety profile of autologous haematopoietic stem cell transplantation following natalizumab therapy in aggressive forms of multiple sclerosis
2015 Mariottini, A; Innocenti, C; Repice, AM; Fani, A; Massacesi, L; Saccardi, R
Impact of new DMAs on the safety profile of patients undergoing autologous haematopoietic stem cell transplantation for Multiple Sclerosis
2016 Innocenti, C; Barilaro, A; Fani, A; Mariottini, A; Massacesi, L; Repice, AM; Saccardi, R
Purely myeloablative conditioning regimen in aggressive multiple sclerosis: two case reports
2016 Innocenti, C; Barilaro, A; Fani, A; Mariottini, A; Massacesi, L; Repice, AM; Saccardi, R
Intermediate intensity regimen in autologous HSCT for severe multiple sclerosis: a large, single center experience
2016 Saccardi, R; Repice, AM; Innocenti, C; Mariottini, A; Amato, MP; Guidi, S; Fani, A; Nistri, R; Giannini, M; Portaccio, E; Barilaro, A; Nozzoli, C; Gozzini, A; Massacesi, L
intermediate intensity regimen in autologous HSCT for severe Multiple Sclerosis: a a large, single center experience
2016 Saccardi, R; Barilaro, A; Fani, A; Giannini, M; Gozzini, A; Guidi, S; Innocenti, C; Mariottini, A; Nozzoli, C; Portaccio, E; Repice, AM; Amato, MP; Massacesi, L
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience
2017 Boffa, G; Sormani, MP; Repice, AM; Curro, D; Capobianco, M; Gualandi, F; Lo Re, M; De Gobbi, M; Innocenti, C; Capello, E; Mariottini, A; Forci, B; Uccelli, A; Barilaro, A; Cottone, S; Bertolotto, A; Saccardi, R; Mancardi, GL; Massacesi, L
Reconstitution of natural or vaccination-driven immunity after aHSCT in multiple sclerosis
2018 Innocenti, C; Amato, MP; Barilaro, A; Bianchini, G; Capobianco, T; Calia, MA; Ceschini, R; Fani, A; Giannini, M; Gozzini, A; Guidi, S; Mariottini, A; Massacesi, L; Nozzoli, C; Repice, A; Rossolini, G; Saccardi, R
Efficacy of autologous hematopoietic stem cell transplantation in secondary progressive Multiple sclerosis
2019 Mariottini, A; Filippini, S; Di Tullio, MG; Forci, B; Innocenti, C; Barilaro, A; Fani, A; Saccardi, R; Massacesi, L; Repice, AM
Management of viral reactivation in multiple sclerosis patients after autologous transplantation with BEAM/ATG conditioning regimen
2019 Innocenti, C; Di Gioia, M; Amato, MP; Ciccone, N; Cutini, I; Giannini, M; Gozzini, A; Guidi, S; Mariottini, A; Massacesi, L; Nozzoli, C; Repice, A; Maria, RG; Saccardi, R
Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
2021 Boffa, Massacesi L, Inglese M, Mariottini A, Capobianco M, Moiola L, Amato MP, Cottone S, Gualandi F, De Gobbi M, Greco R, Scime R, Frau J, Zimatore GB, Bertolotto A, ComiG, Uccelli A, Signori A, Angelucci E, Innocenti C, Ciceri F, Repice AM, Sormani MP, R. Saccardi R, Mancardi GL, and the Italian BMT-MS study group
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis
2021 Mariottini A.; Filippini S.; Innocenti C.; Forci B.; Mechi C.; Barilaro A.; Fani A.; Carlucci G.; Saccardi R.; Massacesi L.; Repice A.M.
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Quale strategia per la gestione dell’anemia in corso di triplice terapia anti-HCV? | 2013 | E.Salomoni; F.Baragli; C.Innocenti; G.Corti | |
CMV AND EBV REACTIVATION AFTER AUTOLOGOUS HAEMOPOIETIC STEM CELL TRANSPLANTATION WITH BEAM CONDITIONING REGIMEN FOR MULTIPLE SCLEROSIS AND LYMPHOMA: A RETROSPECTIVE SINGLE CENTER CASE-CONTROL STUDY | 2014 | Di Gioia, M; Innocenti, C; Donnini, I; Nozzoli, C; Bosi, A; Guidi, S; Rigacci, L; Repice, A; Massacesi, L; Portaccio, E; Amato, MP; Saccardi, R | |
Safety profile of autologous haematopoietic stem cell transplantation following natalizumab therapy in aggressive forms of multiple sclerosis | 2015 | Mariottini, A; Innocenti, C; Repice, AM; Fani, A; Massacesi, L; Saccardi, R | |
Impact of new DMAs on the safety profile of patients undergoing autologous haematopoietic stem cell transplantation for Multiple Sclerosis | 2016 | Innocenti, C; Barilaro, A; Fani, A; Mariottini, A; Massacesi, L; Repice, AM; Saccardi, R | |
Purely myeloablative conditioning regimen in aggressive multiple sclerosis: two case reports | 2016 | Innocenti, C; Barilaro, A; Fani, A; Mariottini, A; Massacesi, L; Repice, AM; Saccardi, R | |
Intermediate intensity regimen in autologous HSCT for severe multiple sclerosis: a large, single center experience | 2016 | Saccardi, R; Repice, AM; Innocenti, C; Mariottini, A; Amato, MP; Guidi, S; Fani, A; Nistri, R; Giannini, M; Portaccio, E; Barilaro, A; Nozzoli, C; Gozzini, A; Massacesi, L | |
intermediate intensity regimen in autologous HSCT for severe Multiple Sclerosis: a a large, single center experience | 2016 | Saccardi, R; Barilaro, A; Fani, A; Giannini, M; Gozzini, A; Guidi, S; Innocenti, C; Mariottini, A; Nozzoli, C; Portaccio, E; Repice, AM; Amato, MP; Massacesi, L | |
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience | 2017 | Boffa, G; Sormani, MP; Repice, AM; Curro, D; Capobianco, M; Gualandi, F; Lo Re, M; De Gobbi, M; Innocenti, C; Capello, E; Mariottini, A; Forci, B; Uccelli, A; Barilaro, A; Cottone, S; Bertolotto, A; Saccardi, R; Mancardi, GL; Massacesi, L | |
Reconstitution of natural or vaccination-driven immunity after aHSCT in multiple sclerosis | 2018 | Innocenti, C; Amato, MP; Barilaro, A; Bianchini, G; Capobianco, T; Calia, MA; Ceschini, R; Fani, A; Giannini, M; Gozzini, A; Guidi, S; Mariottini, A; Massacesi, L; Nozzoli, C; Repice, A; Rossolini, G; Saccardi, R | |
Efficacy of autologous hematopoietic stem cell transplantation in secondary progressive Multiple sclerosis | 2019 | Mariottini, A; Filippini, S; Di Tullio, MG; Forci, B; Innocenti, C; Barilaro, A; Fani, A; Saccardi, R; Massacesi, L; Repice, AM | |
Management of viral reactivation in multiple sclerosis patients after autologous transplantation with BEAM/ATG conditioning regimen | 2019 | Innocenti, C; Di Gioia, M; Amato, MP; Ciccone, N; Cutini, I; Giannini, M; Gozzini, A; Guidi, S; Mariottini, A; Massacesi, L; Nozzoli, C; Repice, A; Maria, RG; Saccardi, R | |
Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis | 2021 | Boffa, Massacesi L, Inglese M, Mariottini A, Capobianco M, Moiola L, Amato MP, Cottone S, Gualandi F, De Gobbi M, Greco R, Scime R, Frau J, Zimatore GB, Bertolotto A, ComiG, Uccelli A, Signori A, Angelucci E, Innocenti C, Ciceri F, Repice AM, Sormani MP, R. Saccardi R, Mancardi GL, and the Italian BMT-MS study group | |
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis | 2021 | Mariottini A.; Filippini S.; Innocenti C.; Forci B.; Mechi C.; Barilaro A.; Fani A.; Carlucci G.; Saccardi R.; Massacesi L.; Repice A.M. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile